By Michael Erman and Julie Steenhuysen Aug 19 (Reuters) - Moderna said on Wednesday that a personalized mRNA cancer vaccine ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

A study involving over 1,100 patients found that combining Moderna and Merck's mRNA vaccine, intismeran, with the immunotherapy Keytruda reduced the risk of melanoma recurrence or death by 49% over ...

Adding the personalized mRNA therapy intismeran autogene to Keytruda cut melanoma recurrence and spread risk after surgery, a Phase 3 trial found. A Phase 3 trial found that adding the individualized ...

Moderna and Merck’s mRNA cancer vaccine, combined with Keytruda, showed promise in preventing melanoma recurrence, according ...

Moderna's mRNA vaccine combined with Merck's immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the ...

A personalised Merck-Moderna mRNA cancer vaccine reduced melanoma recurrence risk when combined with Keytruda, raising hopes ...

Moderna and Merck's mRNA cancer vaccine marks a breakthrough in personalized oncology, with broad financial implications for ...

Moderna and Merck reported promising late-stage trial results for their personalized mRNA cancer vaccine, which lowered the ...